GHTM

Global Health and Tropical Medicine

  • GHTM
    • Vision
    • Mission
    • Governance
    • Scientific Advisory Board
  • News
    • Outreach
    • Events
      • GHTM Sessions
      • Workshops
    • Articles
    • Jobs
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases and pathogens
      • IHC – Individual health care
    • Research in numbers
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases and pathogens
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Technical / administrative support
  • Publications
  • Education
    • Master Theses
    • PhD Theses
  • Services
Home / Archives for Marcelo Sousa-Silva

VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases

  • Autores: Aline Maria Vasconcelos Queiroz, Johny Wysllas de Freitas Oliveira, Cláudia Jassica Moreno, Diego M.A.Guérin, Marcelo Sousa-Silva
  • Ano de Publicação: 2021
  • Journal: Vaccines, 9(3), art 220, [Special Issue: Host Immune Response to Infectious Diseases pp 1 - 9]
  • Link: https://doi.org/10.3390/vaccines9030220

ABSTRACT Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine […]
Ler mais

Insights of antiparasitic activity of sodium diethyldithiocarbamate against different strains of Trypanosoma cruzi

  • Autores: Johny Wysllas de Freitas Oliveira, Taffarel Melo Torres, Cláudia Jassica Gonçalves Moreno, Bruno Amorim-Carmo, Igor Zumba Damasceno, Ana Katarina Menezes Cruz Soares, Jefferson da Silva Barbosa, Hugo Alexandre Oliveira Rocha, Marcelo Sousa-Silva
  • Ano de Publicação: 2021
  • Journal: Scientific Reports, vol 11, art 11200
  • Link: https://doi.org/10.1038/s41598-021-90719-0

ABSTRACT Chagas disease is caused by Trypanosoma cruzi and affects thousands of people. Drugs currently used in therapy are toxic and have therapeutic limitations. In addition, the genetic diversity of T. cruzi represents an important variable and challenge in treatment. Sodium diethyldithiocarbamate (DETC) is a compound with pharmacological versatility acting as metal chelators and ROS generation. Thus, the objective […]
Ler mais

Antimicrobial Activity of Chitosan Oligosaccharides with Special Attention to Antiparasitic Potential

  • Autores: Nayara Sousa da Silva, Nathália Kelly Araújo, Alessandra Daniele-Silva, Johny Wysllas de Freitas Oliveira, Júlia Maria de Medeiros, Renata Mendonça Araújo, Leandro De Santis Ferreira, Hugo Alexandre Oliveira Rocha, Arnóbio Antônio Silva-Junior, Marcelo Sousa-Silva, Matheus de Freitas Fernandes-Pedrosa
  • Ano de Publicação: 2021
  • Journal: Marine Drugs, 19(2), art 110
  • Link: https://doi.org/10.3390/md19020110

ABSTRACT The global rise of infectious disease outbreaks and the progression of microbial resistance reinforce the importance of researching new biomolecules. Obtained from the hydrolysis of chitosan, chitooligosaccharides (COSs) have demonstrated several biological properties, including antimicrobial, and greater advantage over chitosan due to their higher solubility and lower viscosity. Despite the evidence of the biotechnological […]
Ler mais

Antibodies response induced by recombinant virus-like particles from Triatoma virus and chimeric antigens from Trypanosoma cruzi

  • Autores: Aline Maria Vasconcelos Queiroz, Yulia Aleksandrovna Yanshina, Emily Thays da Silva Rodrigues, Fred Luciano Neves Santos, Paola Alejandra Fiorani Celedon, Sweta Maheshwari, Sandra Beatriz Gabelli, Carla Stephanie Peucelle Rubio, Aritz Durana, Diego M.A.Guérin, Marcelo Sousa-Silva
  • Link: https://doi.org/10.1016/j.vaccine.2021.05.039

ABSTRACT ‘Background:’ The infection caused by the protozoan Trypanosoma cruzi affects humans and is called as Chagas disease. Currently, the main measures available to reduce the incidence of this disease are drug treatment and vector control. Traditionally, the development of vaccines occurs mainly through the use of antigenic candidates of the etiologic agent in the […]
Ler mais

African Trypanosomiasis: Extracellular Vesicles Shed by Trypanosoma brucei brucei Manipulate Host Mononuclear Cells

  • Autores: Tatiana Dias-Guerreiro, Joana Palma-Marques, Patrícia Mourata-Gonçalves, Graça Alexandre-Pires, Ana Valério-Bolas, Áurea Gabriel, Telmo Nunes, Wilson Antunes, Isabel Pereira da Fonseca, Marcelo Sousa-Silva, Gabriela Santos-Gomes
  • Ano de Publicação: 2021
  • Journal: Biomedicines, 9(8), 1056
  • Link: https://doi.org/10.3390/biomedicines9081056

ABSTRACT African trypanosomiasis or sleeping sickness is a zoonotic disease caused by Trypanosoma brucei, a protozoan parasite transmitted by Glossina spp. (tsetse fly). Parasite introduction into mammal hosts triggers a succession of events, involving both innate and adaptive immunity. Macrophages (MΦ) have a key role in innate defence since they are antigen-presenting cells and have […]
Ler mais

About GHTM

GHTM is a R&D Center that brings together researchers from IHMT with a track record in Tropical Medicine and International/Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal
+351 213 652 600
+351 213 632 105

  • Facebook
  • YouTube

Subscribe Newsletter

  • How to get to GHTM/IHMT
  • GHTM Sessions
  • Research Groups
  • Cross-cutting issues
© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013